Weather

86°F9:39 PM

Health

1 read

El Paso Residents Eye New Weight-Loss Pills Revolutionizing Treatment Options

KVIA•Thursday, March 19, 2026 at 10:45 AM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

The weight-loss treatment landscape is rapidly evolving with the recent approval of the Wegovy pill, which has quickly gained popularity among about 400,000 Americans. This pill is part of a new wave of GLP-1 medications, with another pill expected to be approved by the FDA next month. Eli Lilly's retatrutide, a promising drug in clinical trials, has shown remarkable weight loss results, averaging 29% over 68 weeks. While these advancements offer hope for effective weight management, concerns arise regarding potential misuse and side effects. Residents should stay informed about these developments as they may impact treatment options and healthcare decisions in El Paso.

Key Details: • Wegovy pill is now used by approximately 400,000 Americans. • A second weight-loss pill is expected to be FDA approved next month. • Retatrutide shows an average weight loss of 29% in trials. • Concerns exist about the misuse of powerful weight-loss medications. • Residents should consult healthcare providers about new treatment options.

el-paso health weight-loss medication glp-1

People & Organizations

El PasoDr. Judith KornerNovo NordiskEli LillyColumbia University Vagelos College of Physicians and SurgeonsBeth Israel Deaconess Medical CenterCharles BarkleyDr. Jody Dushay

Related Articles

Eczema Treatment Cream Recalled Due to Serious Infection Risk

A recall has been issued for the Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, marketed as MG217, after contamination with Staphylococcus aureus was detected. This bacteria poses a significant risk of life-threatening infections, prompting the Food and Drug Administration (FDA) to take action. Consumers using this product should be aware of the potential health hazards associated with it. The recall affects a specific batch of the cream, and users are advised to discontinue its use immediately and consult healthcare professionals if they experience any adverse effects.

Eczema Cream Recall Due to Contamination Risk for El Paso Residents

A recall has been issued for the MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, produced by Pharmacal, after it was discovered to be contaminated with Staphylococcus aureus, a bacteria that can cause severe infections. The FDA announced the recall on Tuesday, highlighting the potential risk of life-threatening staph infections associated with the use of this product. Consumers in El Paso who have purchased this cream should check their medicine cabinets and discontinue use immediately. The recall underscores the importance of monitoring health products for safety concerns.

Cruise Passenger in Nebraska Biocontainment Unit Amid Hantavirus Outbreak

Dr. Stephen Kornfeld, a passenger on the MV Hondius cruise, is currently isolated in a biocontainment unit at the University of Nebraska Medical Center after testing positive for Andes hantavirus. His situation follows an outbreak on the ship, which has resulted in three deaths and several confirmed cases among passengers and crew. As of now, 122 individuals have been evacuated, with ongoing monitoring of 17 Americans and one British dual-national for symptoms. The World Health Organization has confirmed 11 cases related to the cruise, emphasizing that the risk to the general public remains low. Passengers are facing weeks of isolation as health officials conduct assessments and interviews to track the virus's spread.

Argentine Traveler Shares Experience on Hantavirus-Stricken Cruise

Carlos Ferello, an Argentine retiree, was the sole representative from his country aboard the MV Hondius, a cruise ship that recently experienced a hantavirus outbreak, leading to several confirmed cases and three fatalities. After the ship docked in the Canary Islands, Ferello was evacuated and is now in isolation for at least 42 days in Amsterdam. The outbreak began with symptoms in a Dutch passenger, resulting in a tragic chain of events that highlighted the challenges of managing health crises on closed vessels. As of now, nine cases have been confirmed, prompting strict safety measures similar to those during the COVID-19 pandemic, including mask-wearing and social distancing on board. Ferello's story sheds light on the human experience amid a health scare and the resilience of those affected.